natgillin/translations-raw huggingface dataset:
The composition according to claim 26, wherein the beta2-adrenoceptor agonist is selected from enantiomerically pure or enantiomerically enriched R-enantiomer of Amiterol, Bamethan, Bitolterol, Butaxamine, Carbuterol, Cimaterol, Colterol, Clenbuterol, Clorprenaline, Colterol, Deterenol, Dioxethedrin, Etafedrine, Ethylnorepinephrine, Fenoterol, Indacaterol, Isoproterenol, Mabuterol, Meluadrine, Nardeterol, Norbudrine, Norepinephrine, Orciprenaline, Picumeterol, Pirbuterol, Quinprenaline, Reproterol, Salbutamol, Salmeterol, Soterenol, Sulfonterol, Terbutaline, Tulobuterol, Zinterol, a physiologically acceptable derivative thereof and a pharmaceutically acceptable salt thereof. 
Pripravak prema zahtjevu 18, naznačen time da je agonist beta2-adrenoceptora odabran od enantiomerno čistog ili enantiomerno obogaćenog R-enantiomera od Amiterola, Bametana, Bitolterola, Butaksamina, Karbuterola, Cimaterola, Kolterola, Klenbuterola, Klorprenalina, Kolterola, Deterenola, Dioksetedrina, Etafedrina, Etilnorepinefrina, Fenoterola, Indakaterola, Izoproterenola, Mabuterola, Meluadrina, Nardeterola, Norbudrina, Norepinefrina, Orciprenalina, Pikumeterola, Pirbuterola, Kvinprenalina, Reproterola, Salbutamola, Salmeterola, Soterenola, Sulfonterola, Terbutalinea, Tulobuterola, Zinterola, i njegova farmaceutski prihvatljiva sol.
The compound of item 14, which is: or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 
Spoj s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
Device according to claim 6, characterized in that at least one of the housings (28) is formed inside a U-shaped groove. 
Uređaj sukladno jednom od zahtjeva 1 do 6, naznačen time što je najmanje jedno od kućišta (28) formirano unutar utora u obliku slova U.
In general, the central effects manifest as unease, excitation, sleeplessness, fear, shaking fingers, outbreak of sweating and headache. 
Općenito, centralni učinci se manifestiraju kao nelagoda, uzbuđenost, besanica, strah, drhtavi prsti, napadi znojenja 1 glavobolja.
a composition suitable for control of diseases caused by phytopathogens comprising 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od:
Iota-carrageenan for use as claimed in claim 1 or 2, wherein said pathological condition or disease is selected from the group consisting of acute bronchitis, chronic bronchitis, rhinitis, sinusitis, croup, acute bronchiolitis, pharyngitis, tonsillitis, laryngitis, tracheitis, asthma and pneumonia, and wherein said symptom is selected from the group consisting of fever, pain, dizziness, shivering, sweating, and dehydration. 
Jota-karagenan namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se navedeno patološko stanje ili bolest bira iz skupine koju čine akutni bronhitis, kronični bronhitis, rinitis, sinusitis, krup, akutni bronhiolitis, faringitis, tonzillitis, laringitis, traheitis, astma i pneumonija, te što se navedeni simptom bira iz skupine koju čine groznica, bol, vrtoglavica, tresavica, znojenje, te dehidracija.
The pharmaceutical composition of claim 9, for use as a prophylactic or therapeutic vaccine against a HIV, preferably a HIV-1, infection. 
Farmaceutski pripravak prema zahtjevu 9, naznačen time da je za uporabu kao u cjepivo za prevenciju ili liječenje infekcije sa HIV, poželjno infekcije sa HIV-I.
Also preferred is that expression of the nucleic acid is regulated by an inducible promoter, such as alkaline phosphatase promoter, tac promoter, or Ti promoter, and preferably wherein expression of the nucleic acid begins while in the active growth phase of the culturing step. 
Postupak prema bilo kojem od zahtjeva 1-3, naznačen time, da se ekspresija nukleinske kiseline regulira pomoću indukcijskog pokretača, posebno kada indukcijski pokretač je pokretač alkalijske fosfataze, tac-pokretač, ili T7- pokretač.
An antisense oligonucleotide according to claim 4, wherein the nucleotide analogue is defined as a nucleotide having a modified base, and/or a modified sugar moiety and/or a modified internucleoside linkage. 
Besmisleni oligonukleotid u skladu s patentnim zahtjevom 4, pri čemu je analog nukleotida definiran kao nukleotid koji ima modificiranu bazu, i/ili mdificiranu šećernu jedinicu i/ili modificiranu unutarnukleozidnu vezu.
A malonate salt of formula III: 
Malonat formule III ili hidrat te soli:
The method of any one of claims 1-12 further comprising a step of d) purifying the plant derived VLPs from the fraction, preferably the step of purifying comprises filtering the fraction using depth filtration to produce a clarified extract, followed by chromatography of the clarified extract using a cation exchange resin. 
Postupak sukladno patentnom zahtjevu 9 ili 13, naznačen time, da korak pročišćavanja obuhvaća filtriranje frakcije filtriranjem dubine da se dobije pročišćeni ekstrakt, nakon čega slijedi kromatografija pročišćenog ekstrakta upotrebom kromatografije isključenja veličine, kationske izmjenjivačke smole ili afnitetne kromatografije 11 njihove kombinacije.
three heavy chain polypeptide CDRs depicted in SEQ ID NOs: 4, 9, and 14, respectively, or in their conservative sequence variants, and three light chain polypeptide CDRs depicted in SEQ ID NOs: 27, 32, and 37, respectively, or in their conservative sequence variants; 
tri CDRa teških lanaca polipeptida prikazanih u SEQ ID NOs: 4, 9 1 14, respektivno, te tri CDRa lakih lanaca polipeptida prikazanih u SEQ ID NOs: 27, 321 37, respektivno; gdje anti-VAP-1 antitijelo ili njegov vezni dio VAP-1 ima Kp niži od onog kimeričnog anti-VAP-1 antitijela označenog kao BTT-1002; K, je procijenjen Biacore testom površinske rezonancije plazmona.
A DNA polynucleotide comprising a nucleotide sequence that encodes the DNA-targeting RNA of Clause 1. 
(a) prvi nukleotidni slijed, koji kodira RNA koja cilja na DNA, koja sadrži:
The floor elements 18 have lower rims 21 and these rims 21 of adjacent floor elements 18 are placed in abutting relationship to form a closed continuous lower surface of the floor. 
Podni elementi 18 imaju niže rubove 21 1 ovi rubovi 21 susjednih podnih elemenata 18 postavljaju se tako da se upiru kako bi tvorili zatvorenu neprekidnu donju plohu poda.
arranging a semimanufactured component of an upper for a shoe, such that the semimanufactured component of the upper is spread out on a flat surface or on two mutually opposite surfaces; 
- < priprave poluproizvedenog dijela gornjišta (12) za cipelu koje se može rasprostrijeti na ravnoj površini ili na dvije suprotne površine
PET containers of the present invention preferably have a density of between 1.370 g/cc and 1.375 g/cc, more preferably greater than 1.375 g/cc, and most preferably greater than 1.385 g/cc. 
PET posuda iz patentnog zahtjeva 1 ili 2 gdje je gustoća zida između 1.370 g/cc i 1.375 g/cc. PET posuda iz patentnog zahtjeva 1 ili 2 gdje je gustoća zida većaod 1.375 g/cc, poželjno oko 1.385 g/cc.
Then, a suitable reductive agent, such as sodium cyanoborohydride or similar agents such as sodium triacetoxyborohydride, sodium borohydride, tetramethylammonium triacetoxyborohydride, borane-pyridine, dimethylamineborane, triethylamine-borane, tetrahydrofuran-borane, dimethylsulfane-borane, dimethylaniline-borane, diethylaniline-borane is added with eventually a Bronsted or Lewis acid such as hydrochloric acid, acetic acid, trifluoroacetic acid, titanium tetrachloride, zinc chloride and zinc trifluoroacetate, preferably at temperature comprised between 0°C and room temperature, more preferably between 5 and 10°C, and the reaction mixture is then allowed to react for a sufficient time to obtain a satisfactory rate. 
Zatim se doda pogodni reducens, poput natrijevog cijanoborohidrida ili slična sredstva, poput natrijevog triacetoksiborohidrida, natrijevog borohidrida, tetrametilamonijevog triacetoksiborohidrida, boran-piridina, dimetilamin-borana, = trietilamin-borana, tetrahidrofuran-borana, = dimetilsulfan-borana, = dimetilanilin-borana, dietilanilin-borana, uz mogući dodatak Brenstedove ili Lewisove kiseline, poput klorovodične kiseline, octene kiseline, trifluoroctene kiseline, titanijevog tetraklorida, cinkovog klorida i cinkovog trifluoracetata, po mogućnosti na temperaturi između 0 "C i sobne temperature, poželjnije između 5 i 10 "C, te se zatim reakcijsku smjesu ostavi dovoljno vrijeme da reagira kako bi se postiglo zadovoljavajući prinos.
3,4-Dichloro-benzenesulfonyl chloride (60 µL, 0.39 mmol) is added and the reaction mixture is stirred for 10 minutes at ambient temperature. 
Doda se 3,4-diklor-benzensulfonil klorid (60 ul, 0,39 mmolova) 1 reakcijsku smjesu se miješa 10 minuta pri sobnoj temperaturi.
about 300 mg. of netupitant as a free base on day one; 
oko 300 mg netupitanta kao slobodne baze;
or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof. 
-CF3 om ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; naznačen time što se postupak sastoji u: a) obradi spoja formule (7): jej nr
at a position selected from 105, 106, 107, 109, and a combination thereof; 
(a) na položaju odabranom iz 105, 106, 107, 109 1 njihove kombinacije;
Biomaterials as claimed in claim 1, wherein the weight ratio is of 10:90 to 50:50 with a volume-enhancing effect. 
Biomaterijali kako su prijavljeni u patentnom zahtjevu 1, naznačeni time da maseni omjer jest 10:90 do 50:50, a da imaju učinak povećanja volumena.
a sequence consisting of SEQ ID No. 1 
Peptid koji se sastoji od sekvence aminokiselina u skladu s ID BR SEKV 58.
In a preferred embodiment, the step (d) of drying the strands of wood comprises the step of drying the strands for 2 minutes-10 minutes, preferably for 2 minutes-8 minutes, even more preferably for 2 minutes-6 minutes, yet even more preferably for 3 minutes-4 minutes. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da korak (d) sušenje drvenih vlakana obuhvaća korak sušenja vlakana u trajanju od 2 do 10 minuta, poželjno od 2 do 8 minuta, još poželjnije od 2 do 6 minuta i još poželjnije od 3 do 4 minute.
Stirring is continued at 0 °C for 2 hours and then the reaction mixture is poured onto water (15 ml) and extracted with DCM (5 ml). 
Miješanje se nastavi 2 sata pri O*C i zatim se reakcijsku smjesu prelije na vodu (15 ml) i ckstrahira s DCM-om (5 ml).
a targeter-RNA comprising a nucleotide sequence that is complementary to, and hybridizes with, a target sequence of a target DNA inside of one or more target cells of said population of target cells, and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK; i
In certain embodiments, the impurity includes, but is not limited to, 2-acetamido-6-nitrobenzoic acid, N-(3-(2,6-dioxopiperidin-3-yl)-2-methyl-4-oxo-3,4-dihydroquinazolin-5-yl)formamide, and 3-(2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što dodatno uključuje korak prekristaliziranja 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-il)piperidin-2,6-dion-hidroklorida; gdje 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-iI)piperidin-2,6-dion-hidroklorid može imati čistoću koja nije manja od 95%, težinski.
Derivatives include those with V domains defined by polypeptide sequences having at least 80%, preferably at least 90%, most preferably at least 95% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2. 
(b) V domena lanca H ima identičnost slijeda od najmanje 80% sa SEQ ID NO: 1, a V domena lanca L ima identičnost slijeda od najmanje 80% sa SEQ ID NO: 2.
A pharmaceutical formulation comprising (i) ketoprofen, (ii) at least one polyoxyalkylene ester of a hydroxy fatty acid, (iii) at least one hydroxy substituted organic compound selected from the group consisting of at least one alcohol, at least one polyol and mixtures thereof, and (iv) water. 
PATENTNI ZAHTJEVI Farmaceutska formulacija, naznačena time, da sadrži (1) ketoprofen, (11) najmanje jedan polioksialkilen-ester od hidroksi masne kiseline, (iii) najmanje jedan hidroksi-supstituiran organski spoj odabran iz skupine koja se sastoji od najmanje jednog alkohola, najmanje jednog poliola i njihovih mješavina, te (iv) vodu.
The wellbore servicing apparatus according to claim 1, wherein the second mandrel is configured to remain substantially stationary longitudinally along the central axis. 
Uređaj (100) za servisiranje kanala bušotine sukladno Zahtjevu 1, naznačen time da je drugi mandrel (266) konfiguriran na način da u osnovi ostane statičan longitudinalno duž središnje osi (135).
The polypeptide of interest may be of any origin. 
Polipeptid od interesa može biti bilo kojeg podrijetla.
The process of claim 1, wherein said base is selected from the group consisting of triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene 1,4 diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, wherein saidprvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.O0]undec-7-en; te smjese 2 ili višo njih.
or A1 and A2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of: thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, and morpholinyl; wherein said piperidinyl, pyrrolidinyl, piperazinyl, and morpholinyl are optionally substituted with CF3, CH2F, CH2CH2F, C(1-2)alkyl, -CN, OH, CH2OH, F, Cl, OCH3, OCHF2, or OCF3, and up to three additional substituents selected from the group consisting of CH3, and F; 
tiomorfolinil, piperidinil, pirolidinil, piperazinil, i morfolinil; pri čemu su navedeni piperidinil, pirolidinil, piperazinil, i morfolinil proizvoljno supstituirani s CF3, CH2F, CH2CH2F, C(1-2)alkil, -CN, OH, CH2OH, F, Cl, OCH3, OCHF2, ili OCF3, i do tri dodatna supstituenta izabrana iz skupine koju čine CH3, i F;
In an embodiment of the present R4 is selected from the group consisting of hydrogen and methyl, preferably, R4 is hydrogen. In an embodiment of the present invention a is 1. 
R* je izabran iz skupine koja se sastoji od vodika i nižeg alkila; a je cijeli broj od 1 do 2; je izabran iz skupine koja se sastoji od O ff #
The solid oral extended release pharmaceutical dosage form of item 88, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 5, naznačen time da je formulacija matrice s produljenim otpuštanjem bila uskladištena pri 40 *C i 75 "C relativne vlažnosti zraka (RH).
In embodiments where the third polymeric material is a non-ionic polymer, the pH of the inner coating preparation is preferably adjusted prior to coating to be at least 0.5 pH units higher than the pH threshold of the second polymeric material. 
Postupak u skladu s patentnim zahtjevom 11, naznačeno time, da je navedeni treći polimerni materijal je spomenuti neionski polimer, pH unutarnjeg pripravka za prevlačenje se namješta prije premazivanja da bude najmanje 0,5 pH jedinica veći od pH praga drugog polimernog materijala.
a variable light chain comprising amino acid sequences that are at least 95% identical to the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3, and a variable heavy chain comprising amino acid sequences that are at least 95% identical to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4, or 
Izolirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-4, naznačeno time da protutijelo ili njegov fragment protutijela je humaniziran, te pri čemu protutijelo ili njegov fragment protutijela sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 3 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 4.
mg of said quinolone carboxylic acid derivative, wherein said quinolone carboxylic acid is delafloxacin meglumine; and 
(a) 650 mg navedenog derivata kinolon karboksilne kiseline, gdje je navedena kinolon karboksilna kiselina delafloksacin meglumin; i
According to a further aspect of the invention, a particular compound of the invention is 8-((1S)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide; or a pharmaceutically-acceptable salt thereof. 
Kombinacija pogodna za liječenje raka koja sadrži spoj s formulom I, ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 10 i 12 naznačena time da je 8-Â«((1R)-1-(3,5-difluorofenilamino)etil)-N,N-dimetil-2-morfolino-4-okso-4H-kromen-6-karboksamid i taksoid.
In some embodiments of the above objects, the VAP-1 inhibitor is an anti-VAP-1 antibody such as a fully human anti-VAP-1 antibody comprising one to three CDR consensus sequences selected from a group consisting of SEQ ID NOs 1 to 3 and/or a light chain polypeptide comprising one to three CDR consensus sequences selected from a group consisting of SEQ ID NOs 24 to 26. 
Inhibitor VAP-1, koje je posve ljudsko protutijelo protiv VAP-1, koje sadrži jedan do tri konsenzusna CDR slijeda, koje se bira iz skupine koju čine SEQ ID NO 1 do 3 i/ili polipeptid lakog lanca koji sadrži jedan do tri konsenzusna CDR slijeda, koje se bira iz skupine koju čine SEQ ID NO 24 do 26, naznačen time što je namijenjen upotrebi u liječenju fibrotičnog stanja.
2% corn starch, wherein all the % values are expressed in terms of weight percent, and wherein viscosity is in the range 25,000 to 130,000 cP. 
,2% w/w dinatrijevog edetata, i % w/w kukuruznog škroba i naznačen time da je viskoznost u rasponu od 25,000 do 130,000 cP.
making a first modification of the mouse immunoglobulin heavy chain locus, the first modification comprising the placement of one or more human immunoglobulin VH, DH, and JH gene segments or the replacement of one or more sequences in the mouse immunoglobulin heavy chain locus with one or more human immunoglobulin VH, DH, and JH gene segments, wherein said first modification eliminates mouse ADAM6 expression from an endogenous Adam6 allele such that a male mouse having the first modification exhibits a reduced fertility; and 
provođenje prve modifikacije mišjeg lokusa teškog lanca imunoglobulina, pri čemu prva modifikacija uključuje postavljanje jednog ili više humanih imunoglobulina VH, DH i JH genskih segmenata ili zamjenu jednog ili više sljedova u mišjem imunoglobulinskom lokusu teškog lanca s jednim ili više humanih imunoglobulinskih VH, DH i JH genskih segmenata, pri čemu navedena prva modifikacija eliminira ekspresiju ADAM6 miša iz endogenog alela Adam6, tako da muški miš s prvom modifikacijom pokazuje smanjenu plodnost; i
RS, RS' and RS" are each independently selected at each occurrence from hydrogen; C1-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RS, RS' or RS" is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; 
Ls i Ls" su svaki neovisno, odabrani pri svakom pojavljivanju od veze; ili C1-C6alkilena, C2-C6alkenilena ili C2- C6alkinilena, od kojih je svaki neovisno po izboru supstituiran pri svakom pojavljivanju s jednim ili s više Rl; i Rs, Rs’ i Rs" su svaki neovisno odabrani pri svakom pojavljivanju od vodika; C1-C6alkila, C2-C6alkenila ili C2-C6alkinila, od kojih je svaki neovisno po izboru supstituiran s jednim ili s više supstituenata odabranih od halogena, hidroksi, merkapto, amino, karboksi, nitro, okso, fosfonoksi, fosfono, tiokso, formila, cijano or 3- do 6- eročlanog karbocikla ili heterocikla; ili 3- do 6-eročlanog karbocikla ili heterocikla;
In particular, the combination of an M3 antagonist of Formula I with a B2-agonist, such as salmeterol or formoterol, produces significantly and consistently less heart side-effects, such as tachycardia, than a therapeutically equivalent combination of tiotropium bromide with salmeterol or formoterol. 
Osobito kombinacija M3 antagonista sukladno predmetnom izumu s kortikosteroidom poput budesonida ili beklometazona proizvodi znatno i konzistentno povećanje inhibicije kontraktilnog odgovora trahealnog prstena na alergene u usporedbi s terapijski ekvivalentom kombinacijom tiotropij bromida s budesonidom ili beklometazonom.
coupling in registration, preferably by hot pressure gluing, of a strip of said flexible material (43) on said second polycarbonate (PC) layer (42); 
poravnato spajanje, poželjno je postupkom vrućeg lijepljenja pod tlakom, trake navedenog savitljivog materijala (43) na navedeni drugi polikarbonatni (PC) sloj (42);
separating the liquid phase product in an atmospheric distillation tower to recover a fraction comprising hydrocarbons boiling in a range of atmospheric distillates and a first bottoms fraction comprising hydrocarbons having a normal boiling point of at least 340° C.; 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da ostatak ugljikovodične frakcije sadržava ugljikovodike s uobičajenim vrelištem od najmanje 340 *C.
The method of using a composite material as defined in claim 9, wherein the composite material includes 30-95% by weight of the one or more fillers, and 5-70% by weight of the polymerizable resin base. 
Kompozitni materijal kako je definiran u jednom od patentnih zahtjeva 1-10, naznačen time da je za upotrebu u medicini a posebice u zubarstvu.
A process for the preparation of a compound of formula (II) as claimed in claim 3, which comprises: 
HR P20190446 T1 4. - Postupak za pripremu spoja formule (II) sukladno patentnom zahtjevu 3, koji sadrži:
The method of claim 6, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. 
(iv) signalni region 4-IBB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18;
The use according to claim 9, wherein said bioadhesive polymer is selected from the group consisting of methylcellulose, carboxymethylcellulose sodium (CMC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC). 
Upotreba u skladu s patentnim zahtjevom 9, naznačena time što se navedeni bioadhezivni polimer bira iz skupine koju čine metilceluloza, natrij-karboksimetilceluloza (CMC), hidroksietilceluloza (HEC), hidroksipropilceluloza (HPC) 1 hidroksipropilmetilceluloza (HPMC).
The organic reextract solution was washed with 100mL brine then dried over magnesium sulfate and combined with the first organic partition. 
Organska ponovno ekstrahirana otopina je bila isprana sa 100 mL slane vode i tada osušena na magnezij sulfatu i spojena s prvim organskim dijelom.
The immunogenic composition for use according to any one of claims 1-8 wherein the Streptococcus pneumoniae infection occurs in the middle ear and the concentration of Zn2+ in the middle ear is less than 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2 or 0.1µM. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u srednjem uhu, a koncentracija Zn"* u srednjem uhu je manja od 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0,5, 0,2 ili 0,1 uM.
The method of Claim 1 or Claim 2, wherein the mixture is in the form of a spray composition further comprising a propellant. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, gdje je smjesa u obliku raspršivača koja nadalje obuhvaća pokretnu silu.
X is selected from O and S. 
X se bira između Q 1 S.
Latch sub 14 includes extending downwardly from the cylindrical portion 39 a shaft or shank 52 . 
Element 14 zasuna sadrži osovinu ili držač 52 koji sc prostire naniže od cilindričnog dijela 39.